Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 25(11)2024 May 31.
Article in English | MEDLINE | ID: mdl-38892268

ABSTRACT

The cellular distribution and changes in CX3CL1/fractalkine and its receptor CX3CR1 protein levels in the trigeminal subnucleus caudalis (TSC) of rats with unilateral infraorbital nerve ligation (IONL) were investigated on postoperation days 1, 3, 7, and 14 (POD1, POD3, POD7, and POD14, respectively) and compared with those of sham-operated and naïve controls. Behavioral tests revealed a significant increase in tactile hypersensitivity bilaterally in the vibrissal pads of both sham- and IONL-operated animals from POD1 to POD7, with a trend towards normalization in sham controls at POD14. Image analysis revealed increased CX3CL1 immunofluorescence (IF) intensities bilaterally in the TSC neurons of both sham- and IONL-operated rats at all survival periods. Reactive astrocytes in the ipsilateral TSC also displayed CX3CL1-IF from POD3 to POD14. At POD1 and POD3, microglial cells showed high levels of CX3CR1-IF, which decreased by POD7 and POD14. Conversely, CX3CR1 was increased in TSC neurons and reactive astrocytes at POD7 and POD14, which coincided with high levels of CX3CL1-IF and ADAM17-IF. This indicates that CX3CL1/CX3CR1 may be involved in reciprocal signaling between TSC neurons and reactive astrocytes. The level of CatS-IF in microglial cells suggests that soluble CX3CL1 may be involved in neuron-microglial cell signaling at POD3 and POD7, while ADAM17 allows this release at all studied time points. These results indicate an extended CX3CL1/CX3CR1 signaling axis and its role in the crosstalk between TSC neurons and glial cells during the development of trigeminal neuropathic pain.


Subject(s)
CX3C Chemokine Receptor 1 , Chemokine CX3CL1 , Signal Transduction , Animals , Chemokine CX3CL1/metabolism , Rats , CX3C Chemokine Receptor 1/metabolism , CX3C Chemokine Receptor 1/genetics , Male , Microglia/metabolism , Trigeminal Neuralgia/metabolism , Trigeminal Neuralgia/pathology , Neurons/metabolism , Astrocytes/metabolism , Neuralgia/metabolism , Neuralgia/pathology , Rats, Sprague-Dawley
2.
Fluids Barriers CNS ; 17(1): 35, 2020 May 06.
Article in English | MEDLINE | ID: mdl-32375819

ABSTRACT

The choroid plexus (CP) forming the blood-cerebrospinal fluid (B-CSF) barrier is among the least studied structures of the central nervous system (CNS) despite its clinical importance. The CP is an epithelio-endothelial convolute comprising a highly vascularized stroma with fenestrated capillaries and a continuous lining of epithelial cells joined by apical tight junctions (TJs) that are crucial in forming the B-CSF barrier. Integrity of the CP is critical for maintaining brain homeostasis and B-CSF barrier permeability. Recent experimental and clinical research has uncovered the significance of the CP in the pathophysiology of various diseases affecting the CNS. The CP is involved in penetration of various pathogens into the CNS, as well as the development of neurodegenerative (e.g., Alzheimer´s disease) and autoimmune diseases (e.g., multiple sclerosis). Moreover, the CP was shown to be important for restoring brain homeostasis following stroke and trauma. In addition, new diagnostic methods and treatment of CP papilloma and carcinoma have recently been developed. This review describes and summarizes the current state of knowledge with regard to the roles of the CP and B-CSF barrier in the pathophysiology of various types of CNS diseases and sets up the foundation for further avenues of research.


Subject(s)
Central Nervous System Diseases , Cerebrospinal Fluid/metabolism , Choroid Plexus/anatomy & histology , Choroid Plexus/physiology , Homeostasis/physiology , Animals , Central Nervous System Diseases/immunology , Central Nervous System Diseases/metabolism , Central Nervous System Diseases/physiopathology , Humans
3.
Histochem Cell Biol ; 153(4): 239-255, 2020 Apr.
Article in English | MEDLINE | ID: mdl-32020274

ABSTRACT

Glial cells activated by peripheral nerve injury contribute to the induction and maintenance of neuropathic pain by releasing neuromodulating cytokines and chemokines. We investigated the activation of microglia and astrocytes as well as the cellular distribution of the chemokine CCL2 and its receptor CCR2 in the trigeminal subnucleus caudalis (TSC) ipsilateral and contralateral to infraorbital nerve ligature (IONL). The left infraorbital nerve was ligated under aseptic conditions, and sham controls were operated without nerve ligature. Tactile hypersensitivity was significantly increased bilaterally in vibrissal pads of both sham- and IONL-operated animals from day 1 to 7 and tended to normalize in sham controls surviving for 14 days. Activated microglial cells significantly increased bilaterally in the TSC of both sham- and IONL-operated animals with a marked but gradual increase in the ipsilateral TSC from 1 to 7 days followed by a decrease by day 14. In contrast, robust activation of astrocytes was found bilaterally in the TSC of IONL-operated rats from 3 to 14 days with a transient activation in the ipsilateral TSC of sham-operated animals. Cellular distribution of CCL2 varied with survival time. CCL2 immunofluorescence was detected in neurons within 3 days and in astrocytes at later time points. In contrast, CCR2 was found only in astrocytes at all time points with CCR2 intensity being dominant in the ipsilateral TSC. In summary, our results reveal bilateral activation of microglial cells and astrocytes as well as changes in the cellular distribution of CCL2 and its receptor CCR2 in the TSC during the development and maintenance of orofacial neuropathic pain.


Subject(s)
Chemokine CCL2/metabolism , Neuralgia/metabolism , Neuroglia/metabolism , Receptors, CCR2/metabolism , Substantia Gelatinosa/metabolism , Animals , Disease Models, Animal , Male , Rats , Rats, Wistar
4.
Vet J ; 194(3): 354-60, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22704136

ABSTRACT

Mycobacterium avium subsp. paratuberculosis (MAP), the causative agent of paratuberculosis in ruminants, has a lipid-rich cell wall which facilitates its survival and persistence in the environment. This property of the organism is exploited when it is cultured as decontaminating agents and antibiotics are used to suppress the growth of contaminating microflora, but such treatments can also negatively affect the isolation of MAP itself. The objective of this study was to assess the effect of the 'VAN' antibiotics (vancomycin, amphotericin B and nalidixic acid) on the viability of MAP using a propidium monoazide real time quantitative PCR (PMA qPCR) and culture. Long-term (5 week) treatment with VAN antibiotics resulted in a larger decrease in bacterial numbers compared to short-term (3 day) exposure. The PMA qPCR assay indicated that 50 µg/mL of vancomycin, 50 µg/mL of nalidixic acid, and 200 µg/mL of amphotericin B were 'threshold' concentrations, respectively, above which the decline in the viability of MAP was statistically significant. Using culture, these threshold concentrations were 100 µg/mL of vancomycin, 50-100 µg/mL of nalidixic acid, and 100 µg/mL of amphotericin B, respectively. Given that the two methods were found to be comparable, the PMA qPCR is a potentially more convenient and effective alternative to culture in detecting MAP.


Subject(s)
Anti-Bacterial Agents/pharmacology , Azides/metabolism , Colony Count, Microbial/methods , Mycobacterium avium subsp. paratuberculosis/drug effects , Mycobacterium avium subsp. paratuberculosis/isolation & purification , Propidium/analogs & derivatives , Real-Time Polymerase Chain Reaction/methods , Amphotericin B/pharmacology , Animals , Dose-Response Relationship, Drug , Mycobacterium avium subsp. paratuberculosis/growth & development , Mycobacterium avium subsp. paratuberculosis/metabolism , Nalidixic Acid/pharmacology , Paratuberculosis/diagnosis , Paratuberculosis/microbiology , Propidium/metabolism , Ruminants/microbiology , Time Factors , Vancomycin/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...